Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Eli Lilly CDR (CAD Hedged)

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes

Phase 1

Active, not recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY3209590

First Posted Date: 2023-12-14

Last Posted Date: 2024-04-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT06169982

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany

A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Repaglinide
Drug: Pirtobrutinib

First Posted Date: 2023-12-11

Last Posted Date: 2025-03-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT06165146

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

A First-In-Human Study of LY3839840 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3839840
Drug: Placebo
Drug: Midazolam

First Posted Date: 2023-12-01

Last Posted Date: 2025-06-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 140

Registration Number: NCT06153355

Locations: 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States

A Study of LY3971297 in Healthy Participants

Phase 1

Recruiting

Conditions: Obesity
Hypertension
Healthy

Interventions: Drug: LY3971297
Drug: Placebo
Drug: LY3971297 IV

First Posted Date: 2023-11-28

Last Posted Date: 2025-06-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 225

Registration Number: NCT06148272

Locations: 🇯🇵
Hakata Clinic, Fukuoka, Japan
🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

and more 3 locations

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Phase 2

Recruiting

Conditions: Obesity
Overweight

Interventions: Drug: LY3841136
Drug: LY3305677
Drug: Placebo
Drug: Tirzepatide
Drug: LY3549492

First Posted Date: 2023-11-22

Last Posted Date: 2025-05-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1040

Registration Number: NCT06143956

Locations: 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸
HOPE Research Institute, Phoenix, Arizona, United States
🇺🇸
Headlands Research - Scottsdale, Scottsdale, Arizona, United States

and more 51 locations

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus
Healthy

Interventions: Drug: Placebo
Drug: LY3938577
Drug: Insulin degludec

First Posted Date: 2023-11-15

Last Posted Date: 2024-07-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 66

Registration Number: NCT06132126

Locations: 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸
Qps-Mra, Llc, Miami, Florida, United States
🇺🇸
Labcorp CRU, Dallas, Texas, United States

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Phase 2

Active, not recruiting

Conditions: Obesity
Overweight and Obesity

Interventions: Drug: LY3305677
Drug: Placebo

First Posted Date: 2023-11-09

Last Posted Date: 2025-04-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 179

Registration Number: NCT06124807

Locations: 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸
Headlands Research - Scottsdale, Scottsdale, Arizona, United States
🇺🇸
The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson, Arizona, United States

and more 26 locations

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

Phase 1

Terminated

Conditions: Atopic Dermatitis
Healthy

Interventions: Drug: LY3872386
Drug: Placebo
Drug: Prednisone

First Posted Date: 2023-11-07

Last Posted Date: 2024-07-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT06119529

Locations: 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸
Fortrea Clinical Research Unit, Daytona Beach, Florida, United States

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis

Interventions: Drug: LY3537982
Drug: Pembrolizumab
Drug: Placebo
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2023-11-07

Last Posted Date: 2025-06-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1016

Registration Number: NCT06119581

Locations: 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Banner University Medical Center Phoenix, Phoenix, Arizona, United States

and more 421 locations

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3537982
Drug: Digoxin
Drug: Midazolam
Drug: Rosuvastatin

First Posted Date: 2023-11-01

Last Posted Date: 2024-11-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 35

Registration Number: NCT06111521

Locations: 🇺🇸
ICON Early Clinical & Bioanalytical Solutions, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy